BioFactura develops and commercializes high-value biosimilars ie follow-on biologics or generic biopharmaceuticals, biodefense medical countermeasures, and client-selected novel drugs using the firm's patented StableFast Biomanufacturing Platform, a novel system rapidly to generate stable NS0 cell lines for biopharmaceutical manufacturing. Elements of this system include a chemically-defined, serum- and cholesterol-free production medium and pre-adapted parental cells, modular expression vectors that utilize a patented selection strategy, and a proprietary growth supplement that permits rapid generation and cloning of cell lines. This platform is simple to use, fast, and productive. A clonal production cell line can be developed and scaled up to yield over one gram of product in less than eight weeks. In Septmeber 2019 it was announced that BARDA (Biomedical Advanced Research and Development Authority) had awarded BioFactura Inc a $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic/
